People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Medical Devices
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Seahorse Bioscience Inc | — | Biotechnology | Series A | $20.7M | $410.2M | 2012 |
| Optofluidics, Inc. | — | Biotechnology | Series A | $19.4M | $96.7M | 2020 |
| Bioimagene Inc | — | Biotechnology | Series A | $12.0M | $433.8M | 2009 |
| Nanomedical Diagnostics, Inc. | — | Medical Devices | Series A | $12.0M | $38.0M | 2017 |
Joseph Keegan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joseph Keegan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Stone | 1 | 12 |
| Fouad Azzam | 1 | 8 |
| G. Steven Burrill | 1 | 7 |
| William Snider | 1 | 7 |
| Yatin Mundkur | 1 | 7 |
| Harry Wilcox | 1 | 6 |
| Steven Young | 1 | 6 |
| Ajit Singh | 1 | 5 |
| John Dean | 1 | 5 |
| Biao He | 1 | 5 |
| Nina Saberi | 1 | 5 |
| Paul Grint | 1 | 5 |
| Chad Souvignier | 1 | 4 |
| Shahram Hejazi | 1 | 3 |
| Casey McGlynn | 1 | 3 |
| Ross Bundy | 1 | 2 |
| Jeffrey Hurst | 1 | 2 |
| Jay Teich | 1 | 2 |
| Tim Hoerr | 1 | 2 |
| Michael Heltzen | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.